%0 Journal Article
%T The engineered agonistic anti-CD40 antibody potentiates the antitumor effects of β-glucan by resetting TAMs.
%A Cheng W
%A Huang Z
%A Hao Y
%A Hua H
%A Zhang B
%A Li X
%A Fu F
%A Yang J
%A Zheng K
%A Zhang X
%A Qi C
%J Immunol Lett
%V 268
%N 0
%D 2024 Aug 27
%M 38810887
%F 4.23
%R 10.1016/j.imlet.2024.106882
%X Anti-CD40 antibodies (Abs) have been shown to induce antitumor T-cell responses. We reported that the engineered agonistic anti-CD40 Ab (5C11, IgG4 isotype) recognized human CD40 antigen expressed on a human B lymphoblastoid cell line as well as on splenic cells isolated from humanized CD40 mice. Of note, a single high dosage of 5C11 was able to prohibit tumor growth in parallel with an increase in the population of infiltrated CD8+ T cells. Furthermore, the antitumor effects of 5C11 were enhanced in the presence of β-glucan along with an increase in the population of infiltrated CD8+ T cells. In addition, the numbers of CD86+ TAMs and neutrophils were elevated in the combination of 5C11 and β-glucan compared with either 5C11 or β-glucan alone. Furthermore, the abundance of Faecalibaculum, one of the probiotics critical for tumor suppression, was obviously increased in the combination of 5C11 and β-glucan-treated mice. These data reveal a novel mechanism of tumor suppression upon the combination treatment of 5C11 and β-glucan and propose that the combination treatment of agonistic anti-human CD40 antibody 5C11 and β-glucan could be a promising therapeutic strategy for cancer patients.